We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current ADVM market cap is 98.6M. The company's latest EPS is USD -5.6323 and P/E is -0.84.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 1M |
| Operating Income | -34.53M | -26.16M | -26.84M | -20.88M | -29.22M |
| Net Income | -32.89M | -23.71M | -24.79M | -18.48M | -27.13M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 250k | 0 | 7.5M | 0 | 3.6M |
| Operating Income | -68.55M | -117.95M | -146.12M | -157.14M | -123.99M |
| Net Income | -64.49M | -117.51M | -145.54M | -154.54M | -117.17M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 196.77M | 173.01M | 267.83M | 253.8M | 234.38M |
| Total Liabilities | 94.06M | 89.54M | 85.54M | 85.77M | 90.26M |
| Total Equity | 102.71M | 83.47M | 182.29M | 168.03M | 144.12M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 222.73M | 482.57M | 439.73M | 308.37M | 173.01M |
| Total Liabilities | 47.77M | 48.22M | 123.54M | 126.85M | 89.54M |
| Total Equity | 174.96M | 434.35M | 316.19M | 181.52M | 83.47M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -69.57M | -90.9M | -23.25M | -43.09M | -64.21M |
| Investing | 106.75M | 96.88M | -22.03M | -24.35M | -37.7M |
| Financing | -97k | 69k | 119.88M | 119.76M | 119.76M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -49.17M | -79.29M | -107.83M | -108.09M | -90.9M |
| Investing | -68.07M | -280.17M | 78.71M | 141.72M | 96.88M |
| Financing | 28.19M | 355.99M | 2.4M | 607k | 69k |
| Market Cap | 98.6M |
| Price to Earnings Ratio | -0.84 |
| Price to Sales Ratio | 27.38 |
| Price to Cash Ratio | 1.31 |
| Price to Book Ratio | 1.18 |
| Dividend Yield | - |
| Shares Outstanding | 20.8M |
| Average Volume (1 week) | 251.6k |
| Average Volume (1 Month) | 228.68k |
| 52 Week Change | -40.01% |
| 52 Week High | 29.80 |
| 52 Week Low | 4.59 |
| Spread (Intraday) | 0.49 (9.82%) |
| Company Name | Adverum Biotechnologies Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.adverum.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
